Who is the CEO of Meta Infotech Ltd?
- Answer Field
-
The CEO of Meta Infotech Ltd. is Venu Gopal Peruri.
BAJAJ BROKING
Asston Pharmaceuticals Limited, established in 2019, is engaged in the manufacturing and export of pharmaceutical and nutraceutical products. With operations spanning across various Asian and African markets, the company offers a broad range of formulations including tablets, capsules, syrups, ointments, gels, and sachets. It focuses on therapeutic categories such as antibiotics, antifungals, analgesics, vitamins, and mineral supplements. Asston operates through both direct sales and contract manufacturing, following a principle-to-principle model with marketers. The company has obtained FDA certifications from central and state authorities and is accredited by NQA, ensuring adherence to recognised quality standards.
With a team of 46 permanent and 6 contractual employees, the company also partners with WHO-GMP certified manufacturers and FDA-approved labs. This setup helps maintain consistent product quality from production to export. Its portfolio includes commonly used formulations like Albendazole USP 400 mg, Diclofenac 100 mg, Ibuprofen-Paracetamol combinations, and Ferrovit Syrup, catering to a wide range of healthcare needs.
For more details, visit the Asston Pharmaceuticals IPO page.
Details | Information |
IPO Date | July 9, 2025 to July 11, 2025 |
Issue Size | 22,41,000 shares (aggregating up to ₹27.56 Cr) |
Price Band | ₹115 to ₹123 per share |
Lot Size | 1000 shares |
Listing At | BSE SME |
Market Maker | JSK Securities and Services Private Limited |
Carry out the Offer for Sale
Achieve the benefits of listing the Equity Shares on the Stock Exchanges
Event | Date |
---|---|
IPO Open Date | Wed, Jul 9, 2025 |
IPO Close Date | Fri, Jul 11, 2025 |
Tentative Allotment | Mon, Jul 14, 2025 |
Initiation of Refunds | Tue, Jul 15, 2025 |
Credit of Shares to Demat | Tue, Jul 15, 2025 |
Tentative Listing Date | Wed, Jul 16, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on July 11, 2025 |
₹115 to ₹123 per share
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,46,000 |
Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,46,000 |
S-HNI (Min) | 3 | 3,000 | ₹3,69,000 |
S-HNI (Max) | 8 | 8,000 | ₹9,84,000 |
B-HNI (Min) | 9 | 9,000 | ₹11,07,000 |
Log in to Your Trading Account
Access your trading account through your broker’s platform.
Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Select Asston Pharmaceuticals IPO
Find "Asston Pharmaceuticals IPO" and click on the ‘Apply’ button.
Enter Application Details
Specify the number of lots (minimum lot size: 1000 shares) and the bid price within the range of ₹115 to ₹123 per share.
Provide Your UPI ID
Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit
Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on July 11, 2025, to complete your application process.
Total Assets: Grew from ₹13.69 crore in FY23 to ₹31.83 crore as of May 2025.
Revenue: Reached ₹6.21 crore in FY25.
Profit After Tax (PAT): Stood at ₹1.32 crore for May 2025.
Net Worth: Recorded at ₹12.04 crore in FY25.
Reserves and Surplus: Recorded at ₹5.77 crore (May 2025), growing steadily over the years.
EBITDA: Stood at ₹1.93 crore in May 2025.
The company has witnessed a steady increase in its total assets, reflecting its expansion efforts and operational growth.
Its revenue generation has shown a consistent upward trend, indicating a growing demand for its products in domestic and international markets.
Profitability has improved over time, pointing to effective cost management and operational efficiency.
The company’s net worth has strengthened, showcasing improved financial health and stability.
Reserves and surplus have grown gradually, supporting reinvestment and future expansion strategies.
Operational performance, as seen in earnings before interest, tax, depreciation, and amortisation, suggests a focus on improving margins and sustainable profitability.
The company’s scale of operations and workforce is relatively modest, which may limit its ability to manage large-scale expansion or face industry disruptions.
Heavy reliance on third-party manufacturers, even if certified, could affect quality control, timelines, or compliance if not closely monitored.
Presence across Asian and African markets, along with a broad therapeutic product range, positions the company to cater to growing international healthcare needs.
Collaborations with certified manufacturers and compliance with recognised quality standards provide a foundation for potential market expansion and client acquisition.
KPI | Values |
ROE | 50.56% |
ROCE | 51.25% |
Debt/Equity | 0.68 |
RoNW | 40.36% |
PAT Margin | 17.27% |
EBITDA Margin | 24.60% |
Price to Book Value | 12.07 |
Registrar | Lead Manager(s) |
---|---|
Maashitla Securities Private Limited | Sobhagya Capital Options Ltd |
Asston Pharmaceuticals Ltd.
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: http://www.asstonpharmaceuticals.com/
Asston Pharmaceuticals Limited operates in the pharmaceutical and nutraceutical manufacturing space with a focus on exports to Asian and African markets. The company’s offerings cover a wide range of therapeutic categories, and its business model includes both direct sales and contract manufacturing. Certifications from recognised regulatory bodies support its compliance with industry standards.
The IPO is aimed at carrying out an offer for sale and achieving the benefits of listing on the stock exchange. With a defined product portfolio, operational structure, and export presence, the company maintains its focus on consistent production and market engagement across geographies.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Asston Pharmaceuticals IPO.
Share this article:
No result found
The CEO of Meta Infotech Ltd. is Venu Gopal Peruri.
The Asston Pharmaceuticals IPO will open for subscription from July 9, 2025, to July 11, 2025.
Asston Pharmaceuticals Limited is engaged in the manufacturing and export of pharmaceutical and nutraceutical products. The company operates across various therapeutic categories and follows a mix of direct sales and contract manufacturing. Its business model involves partnerships with certified manufacturers and has regulatory accreditations, which support ongoing operations. Sustainability depends on market demand, regulatory compliance, and continued operational efficiency.
The issue size is 22,41,000 equity shares, aggregating up to ₹27.56 crore.
'Pre-apply' allows investors to submit their IPO applications before the official opening date. These applications are processed once the IPO opens, helping investors avoid last-minute delays or technical issues.
You will receive a confirmation from your broker or trading platform once your UPI mandate is approved and your IPO application is successfully submitted.
The lot size for the IPO is 1,000 shares, and the minimum order quantity for retail investors is 2 lots, i.e., 2,000 shares.
The tentative allotment date for the IPO is Monday, July 14, 2025.
The registrar for the Asston Pharmaceuticals IPO is Maashitla Securities Private Limited.
As of the information available in the Red Herring Prospectus, there are no specific governance concerns or red flags publicly highlighted regarding the leadership or board structure. Investors may review the prospectus and regulatory filings for detailed disclosures.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading